Sat.Dec 19, 2020 - Fri.Dec 25, 2020

article thumbnail

Merck signs $356M deal to supply US with experimental coronavirus drug

Bio Pharma Dive

The drugmaker spent $425 million a month ago to acquire the biotech developer of the treatment, which tamps down on the body's inflammatory response to viral infections.

Drugs 364
article thumbnail

Is DTC effective?

World of DTC Marketing

According to a study in the Journal for American Board of Family Medicine “respondents (76%) said they were likely to ask a health care provider about advertised drugs; 26% said they had already done so. Among the 26% of respondents who talked to a health care provider about a specific prescription drug they saw advertised, 16% said they received a prescription for the advertised drug.

Doctor 249
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

EU nod for first long-acting HIV injectable treatment

Pharma Times

Rekambys plus Vocabria authorised to treat HIV-1 infections in adults who are virologically suppressed

156
156
article thumbnail

Boston Doctor Develops Severe Allergic Reaction After Getting Moderna Vaccine

NY Times

The patient, who has a severe shellfish allergy, recovered quickly with treatment. Until now, reports of severe reactions had been linked to the Pfizer vaccine.

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

FDA grants approval to Ebola drug from Ridgeback

Bio Pharma Dive

In a landmark study, fewer people given Ebanga died from Ebola virus infection than did those who received a control drug. Results from the trial also led to an OK for Regeneron's drug Inmazeb.

Drugs 345
article thumbnail

Should pharma be in the app business?

World of DTC Marketing

Consumers downloaded 204 billion apps in 2019, and mobile use has been increasing during the pandemic. Apple, with its new privacy requirements, is challenging app developers and brands while Facebook cries fowl. It will have little effect on app use, though, for consumers. In 2020, there should be over 592 million daily app downloads, and a survey by Gallup revealed that nearly half (45%) of Americans have at least tried digital health products such as fitness trackers or mobile health apps.

Doctor 230

More Trending

article thumbnail

Therapeutics for ‘COVID-19 Long-Haulers’ Exploding onto the Scene as 2020 Ends

BioSpace

BioSpace spoke with just a couple of companies endeavoring to make 2021 a happier new year for survivors now suffering from the life-altering after-effects of COVID-19.

145
145
article thumbnail

Agios, changing its identity, to sell cancer drug business to Servier

Bio Pharma Dive

Servier will pay Agios $1.8 billion upfront to acquire the biotech's approved leukemia treatment Tibsovo as well as the rest of its pipeline in cancer and early-stage research work.

Drugs 336
article thumbnail

Pharma has a long way to go

World of DTC Marketing

It’s hard to believe that 2020 is almost over but goodbye and good riddance. I’m hoping a new leader can restore the CDC and FDA’s trust and that the nationwide vaccination problem can proceed, but there are bigger issues. Long after COVID is a bad memory, the pharma industry will still be making more and more mistakes in the name of profits.

article thumbnail

Ivory Coast creates first marine protected area

Scienmag

Credit: CEM Ivory Coast has announced the creation of its first Marine Protected Area (MPA). The MPA will cover 2,600km2 (1,000 square miles) of pristine ocean off the coast of Grand-Béréby, protecting marine biodiversity including threatened shark and turtle species. The announcement is the culmination of years of work by the Ivorian government, the Abidjan […].

143
143
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Green light for AZ’s Tagrisso in early-stage lung cancer

Pharma Times

EGFR-TKI approved in the US for early non-small cell lung cancer

142
142
article thumbnail

US pays another $2B to buy more doses of Pfizer, BioNTech coronavirus vaccine

Bio Pharma Dive

The new deal will provide the U.S. with 100 million additional doses of Pfizer and BioNTech's shot, but the much-needed supply won't be available for several months.

article thumbnail

The best to all

World of DTC Marketing

This year I passed 750,000 readers and I could not be more thrilled. I know you love the industry as much as I do and that there is much work still to be done. May you holiday season be filled with great memories. The post The best to all appeared first on World of DTC Marketing.com.

143
143
article thumbnail

DNA analysis could pinpoint ‘long haulers’ among COVID-19 patients

Outsourcing Pharma

The analytical tool, developed via Bionano Genomics, maps structural variations in DNA that are known to cause disease and are tied to symptom severity.

DNA 141
article thumbnail

The New Age of Decentralized Clinical Trials

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

article thumbnail

Pfizer, BioNTech win EU authorisation for COVID-19 vaccine Comirnaty

Pharma Times

Follows positive opinion issued by EMA's CHMP

article thumbnail

Cancer case puts UniQure's hemophilia gene therapy on hold, raising alarms

Bio Pharma Dive

The FDA halted the AMT-061 program, which could be the first approved gene therapy for hemophilia B, because a patient who received the treatment appears to have developed liver cancer.

article thumbnail

Botanical Solution Inc. (BSI) Secures $3.3 Million in Funding with Second Round Planned for Spring 2021

Pharma Mirror

Davis, CA: Botanical Solution Inc. (BSI), innovator of sustainable, highly consistent and cost effective Advanced Botanical Materials, has successfully secured $3.3 million in a seed round of funding, and is planning another round of funding for Spring 2021. The Spring 2021 Round of funding will boost BSI’s proven ability to discover and develop novel botanical products that are sustainable, highly consistent and cost effective.

article thumbnail

NHS leaders urge UK government to extend Brexit transition period

pharmaphorum

NHS leaders have written to the UK prime minister urging him to extend the Brexit transition period by a month to avoid plunging the healthcare service into chaos on 1 January. The letter, published today by the NHS Confederation – a membership organisation representing NHS leaders from all parts of the health service, outlines concerns about the impact a no-deal outcome will have on delivering care to patients amid winter pressures and a rapid rise in COVID-19 infections. “The failu

Medicine 128
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

AMO Pharma launches late-stage study of CMD candidate

Pharma Times

REACH-CDM study was based on results of positive phase II data

130
130
article thumbnail

With biosimilars looming, Roche makes case for new biologic eye drug

Bio Pharma Dive

Twelve-week dosing for faricimab would help Roche's competitive position, but copycat drugs for existing treatments could soon flood the market.

Drugs 205
article thumbnail

Benefits of Medical Software Company Products

Pharma Mirror

During the last couple of years, medical software has gained a lot of momentum. It’s crucial for monitoring the health of patients, and it’s one of the best ways to put human ingenuity to use. The market for this niche is getting bigger, and it’s going to cross 30 billion dollars soon. Managers and local clinics need to know about all the benefits of using these kinds of programs.

article thumbnail

Study Suggests Link Between Sleep Supplement and COVID-19

BioSpace

At the moment, eight clinical trials are currently being carried out to determine if the link between melatonin and the novel coronavirus is legitimate.

article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

Aimmune’s peanut allergy med Palforzia wins EU approval

Pharma Times

Drug becomes first treatment for peanut allergy in the EU

Allergies 130
article thumbnail

Vertex teams up with Skyhawk, leaning on another biotech in bid to diversify

Bio Pharma Dive

Following a string of deals in edgy, unproven fields of scientific research, Vertex's latest diversification push involves chemical-based drugs that target RNA — an approach that's already attracted several large pharmas.

RNA 200
article thumbnail

UK prepares for decision on AZ/Oxford vaccine as COVID cases soar

pharmaphorum

The UK’s COVID-19 vaccination programme could get a speed boost, with the country’s drugs regulator expected to make a decision on a shot from Oxford University/AstraZeneca in the next few days. If the vaccine becomes available the UK will be able to step up its vaccination programme as large swathes of the country face draconian “Tier 4” restrictions due to the emergence of as more infectious variant.

article thumbnail

'Highly likely' that COVID-19 vaccine protects against new UK variant: BioNTech

BioPharma Reporter

BioNTech's CEO says it is highly likely that the Pfizer/BioNTech vaccine will be able to deal with the new variant that has emerged in the UK. And a new vaccine could be developed within six weeks if needed.

article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

EU green light for Zogenix’s Fintepla

Pharma Times

Oral solution approved to treat seizures associated with Dravet syndrome

129
129
article thumbnail

FDA delays decision on Novartis cholesterol therapy

Bio Pharma Dive

The regulator declined to approve inclisiran, which Novartis acquired in its buyout of The Medicines Co., after agency staff weren't able to inspect a production facility in Europe.

article thumbnail

The top 5 pharma M&A deals of 2020

pharmaphorum

2020’s M&A activity hasn’t quite reached the heights of last year’s, where two pharma mega-mergers – BMS’ buyout of Celegne and AbbVie’s acquisition of Allergan – accounted for almost 40% of total M&A deal values. That said, there were still some interesting moves indicating new directions of travel for big pharma players – with most deals focused on specific drugs from biotechs, particularly in cancer (though we did get rumours of an AstraZeneca-Gilead merger , which would have been the

Sales 126
article thumbnail

Wishing You More Affordable Medicine This Christmas

Pharmacy Checkers

With some stops and starts, this blog has become far more focused on policy, regulatory matters, law and politics — and less on everyday consumer issues relating to drug prices. With Christmas upon us, I want to extoll PharmacyChecker.com’s simple core mission: make it easier for Americans to pay for their prescription drugs. Ask PharmacyChecker , the consumer journalistic section of PharmacyChecker, has a great piece up today called The Gift of Low Drug Prices.

Medicine 119
article thumbnail

The New Age of Decentralized Clinical Trials

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.